THE ABSCOPAL EFFECT
CRYOABLATION & IMMUNITY
The abscopal effect — regression of untreated tumour lesions after local cryoablation — represents the clearest clinical evidence that destroying one tumour can activate the immune system to attack others. Understanding why cryoablation triggers this effect better than most other local treatments is reshaping how we think about ablation in the immunotherapy era.
analyticsAt a Glance
- check_circleThe abscopal effect was first described with radiotherapy but occurs more reliably with cryoablation due to intact antigen release
- check_circleCryoablation releases damage-associated molecular patterns (DAMPs) that activate dendritic cells and initiate a primed T-cell response
- check_circleClinical cases of abscopal regression after cryoablation have been documented in melanoma, RCC, NSCLC, and breast cancer
- check_circleCombining cryoablation with checkpoint inhibitors amplifies the abscopal effect — the basis of cryoimmunotherapy
What Is the Abscopal Effect?
The word 'abscopal' comes from the Latin ab (away from) and scopus (target). It describes a phenomenon where treating one tumour lesion — with radiation, ablation, or other local therapy — causes regression of entirely separate, untreated tumour lesions at distant anatomical sites.
“The abscopal effect is the immune system doing exactly what we want it to do: recognising the tumour as foreign and attacking it everywhere — not just where we pointed the instrument.”
First Described with Radiotherapy
The abscopal effect was first formally described in 1953 by R.H. Mole following radiotherapy. Cases were rare and poorly understood for decades — until checkpoint inhibitors revealed that these responses were immune-mediated, reproducible, and potentially amplifiable by combining radiation or ablation with immunotherapy.
Why It Matters for Metastatic Disease
For patients with metastatic cancer, the promise of the abscopal effect is profound: a single percutaneous procedure on one accessible lesion could, in the right immunological context, trigger the patient's own immune system to control or regress lesions elsewhere — including in locations unsuitable for ablation or surgery.
The Immune Mechanism Behind Cryoablation's Abscopal Effect
The abscopal effect is now understood as a six-step immune cascade. Each step can be enhanced — or inhibited — by the characteristics of the local treatment used.
- 1
Immunogenic Cell Death
Freeze-thaw cycles cause tumour cells to release damage-associated molecular patterns (DAMPs): calreticulin migrates to the cell surface, HMGB1 and ATP are secreted into the extracellular space. These are 'danger signals' the immune system recognises as distress.
- 2
Dendritic Cell Activation
DAMPs bind pattern recognition receptors on resident dendritic cells, activating them. Activated dendritic cells engulf intact tumour debris — which cryoablation releases far better than heat-based ablation, which denatures proteins — and migrate to regional lymph nodes.
- 3
Neoantigen Presentation
In the regional lymph node, activated dendritic cells present tumour-specific neoantigens to naive CD8+ T-cells via MHC class I molecules. This primes a clone of cytotoxic T-cells specific to the patient's own tumour antigens.
- 4
T-Cell Expansion and Trafficking
Primed tumour-specific T-cells proliferate and enter the systemic circulation. They traffic throughout the body guided by chemokine gradients — including toward distant tumour deposits expressing the same antigens.
- 5
Immune Synapse at Distant Tumours
Cytotoxic T-cells infiltrate untreated metastatic lesions, recognise tumour cells expressing the matching antigen-MHC complex, and initiate target-cell killing. This is the abscopal response — occurring at sites the surgeon or radiologist never touched.
- 6
Sustained Immune Memory
Successfully activated anti-tumour T-cell responses may generate long-lived memory T-cells, providing durable immune surveillance. This is the theoretical basis for sustained remissions observed in some cryoimmunotherapy case reports.
Why Cryoablation Triggers the Abscopal Effect Better Than Radiotherapy or Heat Ablation
Not all local tumour destruction produces the same immune activation. The antigenicity of the material released — and the inflammatory context in which it is presented — determines whether the immune system responds or ignores the cellular debris.
“Heat ablation at 60–100°C denatures the very proteins the immune system needs to recognise. Cryoablation preserves them — intact antigens, delivered into a danger-signal rich inflammatory environment.”
Heat Ablation (RFA / MWA): Limited Immune Activation
Temperatures above 60°C irreversibly denature proteins, including the tumour-specific neoantigens that T-cells recognise. Heat also triggers coagulative necrosis — a form of cell death that releases fewer immunostimulatory signals than the immunogenic cell death produced by freeze-thaw cycles. In comparative preclinical studies, RFA generates significantly less dendritic cell activation than cryoablation.
Radiotherapy: Partial Immune Activation
Radiation produces immunogenic cell death and antigen release, but the abscopal effect after radiotherapy alone is rare in clinical practice — estimated at <1% of irradiated patients. Radiation also directly damages lymphocytes infiltrating the treatment field, and local immunosuppression in the irradiated volume can blunt the initial T-cell response.
Cryoablation: Maximum Antigen Preservation
Freeze-thaw cycles at –40°C to –150°C cause osmotic cell lysis rather than protein denaturation — releasing structurally intact tumour antigens alongside DAMPs into the surrounding tissue. This produces the most immunostimulatory debris of any ablation modality, consistently generating higher intratumoural T-cell infiltration in both preclinical and early clinical data.
Documented Abscopal Responses After Cryoablation
Published case reports and prospective series documenting objective abscopal responses — regression of untreated lesions — following cryoablation, with and without concurrent immunotherapy.
| Tumour Type | Setting | Abscopal Response | Reference / Context |
|---|---|---|---|
| Metastatic RCC | Cryo + ipilimumab (Phase II) | 27% objective response rate in untreated lesions | Kato et al.; key early cryoimmunotherapy trial |
| Metastatic Melanoma | Cryo alone (case series) | Complete regression of untreated skin and LN metastases | Sporadic case reports; immune mechanism confirmed by biopsy |
| NSCLC with liver metastases | Cryo + nivolumab (pilot) | Partial response in liver lesions after lung cryo | Phase I/II pilot data; multicentre ongoing |
| Metastatic Breast Cancer | Cryo + pembrolizumab (trial) | Increased TIL density in untreated lesions post-cryo | Translational data from ongoing Phase II trial |
| Colorectal with lung mets | Liver cryo + anti-PD-L1 | Stabilisation and partial regression in lung lesions | Retrospective series; prospective confirmation pending |
| Prostate Cancer (CRPC) | Cryo + ipilimumab (Phase II) | PSA responses in 8/19 patients; T-cell activation confirmed | Alliance trial; systemic immune response confirmed biologically |
The Promise vs The Current Limitations
The abscopal effect is real, documented, and mechanistically understood — but it remains an inconsistent clinical phenomenon rather than a predictable treatment outcome.
What the Evidence Supports
- Immune activation is consistently documentedIncreased intratumoural T-cell density, dendritic cell activation, and circulating tumour-specific T-cells are reproducibly observed after cryoablation in translational studies.
- Objective abscopal responses have been observedIn cryoimmunotherapy trials — particularly with RCC and ipilimumab — objective responses in untreated lesions meet formal radiological response criteria, not just subjective impression.
- Mechanism is biologically coherentThe immunogenic cell death pathway — DAMPs, dendritic cell activation, neoantigen presentation, T-cell expansion — is well characterised in preclinical and translational data.
- Combination with checkpoint inhibitors amplifies responseAnti-CTLA-4 and anti-PD-1 agents remove regulatory brakes on the T-cell response generated by cryoablation, consistently increasing response rates in combination vs monotherapy.
What Remains Uncertain
- Not all patients respondAbscopal responses occur in a minority — estimated 20–30% — of patients treated with cryoablation plus checkpoint inhibitors. Predictive biomarkers have not been validated clinically.
- No Phase III evidence yetAll cryoimmunotherapy trials to date are Phase I/II. No randomised Phase III trial has demonstrated an overall survival benefit for the combination over standard of care.
- Optimal lesion and timing unclearWhich lesion to ablate for maximum immune activation, how many lesions to treat, and the precise timing relative to checkpoint inhibitor dosing are not yet protocol-standardised.
- Immunosuppressive tumour microenvironment can block responseHighly immunosuppressive tumours (regulatory T-cells, M2 macrophages, TGF-β) may prevent even a well-primed T-cell response from penetrating and eliminating untreated metastases.
More from the Cryoablation Therapy Resource Library
Continue exploring cryoablation — from the technology and procedure experience to disease-specific applications.
- Cryoablation Therapy — Complete Treatment Guide
- Cryoimmunotherapy: Combining Cryoablation with Checkpoint Inhibitors
- Cryoablation vs RFA vs MWA: Which Ablation Is Right for You?
- Cryoprobe Technology: Argon Systems and Multi-Probe Arrays
- Cryoablation for Liver Tumours: HCC and Metastases
- Cryoablation for Bone Metastases: Pain Control and Local Treatment
Frequently Asked Questions
Common questions from patients who have read about the abscopal effect and want to understand its relevance to their case.
Understanding the Abscopal Effect
If I have cryoablation, can it treat my other metastases too?
In some patients — particularly those whose immune systems are primed by concurrent checkpoint inhibitor therapy — cryoablation of one lesion has produced objective responses in distant, untreated metastases. This abscopal response is real and documented in clinical trials. However, it is not predictable enough to rely on as the primary treatment strategy for your metastases. Cryoablation should be planned to achieve local control of the treated lesion; any systemic abscopal benefit is a potential additional gain, not a guaranteed one.
Why is cryoablation better than radiotherapy for triggering immune responses?
The key difference is what happens to tumour antigens. Radiotherapy and heat ablation damage or denature the tumour proteins that T-cells need to recognise as targets. Cryoablation's freeze-thaw mechanism lyses cells osmotically rather than thermally — releasing structurally intact proteins, lipids, and nucleic acids into the surrounding tissue. These intact antigens, delivered alongside danger signals like calreticulin and HMGB1, produce a stronger and more specific dendritic cell activation than the denatured debris from heat ablation.
My tumour is in multiple sites — should I ask about cryoimmunotherapy?
If you have metastatic cancer with at least one lesion that is technically accessible for cryoablation and you are being considered for checkpoint inhibitor therapy (or are already receiving it), discussing cryoimmunotherapy with a specialist is reasonable. The combination does not add substantial additional toxicity to checkpoint inhibitor monotherapy, and there is growing evidence — particularly for RCC, melanoma, and NSCLC — that it can enhance systemic anti-tumour responses. CancerFax can facilitate a specialist review of your case to assess whether you meet eligibility criteria for available cryoimmunotherapy protocols in China or India.
Is the abscopal effect the same as a complete response to immunotherapy?
Not exactly. A complete response to immunotherapy means all detectable disease has regressed — including sites never directly treated. An abscopal response specifically refers to regression of untreated lesions attributable to the immune stimulation from a local procedure (cryoablation or radiation). In practice, an abscopal response can contribute to a complete response when combined with checkpoint inhibitors, but the two terms describe different phenomena. An abscopal response after cryo + anti-PD-1 therapy typically manifests as partial regression at untreated distant sites — profound complete responses involving all metastases are less common and represent the upper end of the response spectrum.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could Cryoablation Trigger a Systemic Response in Your Case?
CancerFax connects patients with immuno-oncology specialists in China and India who integrate cryoablation into immune-oncology strategies — particularly for metastatic cases where systemic immune activation is a treatment goal alongside local tumour control.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.